Previous 10 | Next 10 |
home / stock / pcsa / pcsa articles
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of ...
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 1% on Thursday. The Dow traded down 0.02% to 3...
Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares are trading lower by 23% to $0.21 during Thursday’s session after the company announced it ...
Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515 million contract wi...
Processa Pharmaceuticals Inc (NASDAQ: PCSA) provides an interim analysis from its Phase 1b Next Generation Capecitabine (NGC-Cap) study. ...
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision on Wednesday. The Dow traded up 0.58% ...
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...
U.S. stocks traded higher midway through trading, following the release of PPI data on Wednesday. The Dow traded up 0.06% to 36,598.24 while the NA...
Processa Pharmaceuticals Inc (NASDAQ: PCSA) shares are trading lower by 21.7% to $0.64 Wednesday morning after the company said it recently ha...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...